Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

Chan, Hung-Pin; Liu, Wen-Shan; Liou, William W.; Hu, Chin-Yuan; Chiu, Yu-Li; Peng, Nan‐Jing

doi:10.21873/invivo.11797

Cited by 15 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, PET/CT contributed to the detection of 14.8% of secondary cancers in this study, but there was no statistical difference with respect to secondary cancer incidence. In a previous study involving cancer screening, the cancer detection rate of PET/CT in asymptomatic patients was 1.2-1.44% and most of these cancers were at an early clinical stage [27,28]. Although PET/CT contributes to early detection of secondary cancers in this study, the detection rate was not changed.…”

Section: Discussionmentioning

confidence: 52%

Factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: A multicenter retrospective study

Hong

Shin

Kim

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. Methods We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000 and December 31, 2005 from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio was compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. Results A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2–19.6) years. A total of 183 secondary cancers (5.6%), which included 162 solid and 21 hematologic cancers occurred in 173 patients. There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. Conclusion We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose.

show abstract

Section: Discussionmentioning

confidence: 52%

Factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: A multicenter retrospective study

Hong

Shin

Kim

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The most commonly used tracer is fluorine-18-fluorodeoxyglucose ( 18 F -FDG). FDG-PET is an imaging method based on the increased rate of glucose metabolism ( 23, 24 ) and is sufficient for monitoring therapeutic effects in most malignancies; however, its role in brain oncology is limited, as it exhibits low specificity due to its accumulation in all hyper metabolic cells, specifically glucose-avid normal brain cells ( 25 ).…”

Section: Introductionmentioning

confidence: 99%

Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma

Nisnboym

Vincze

Xiong

et al. 2023

Cancer Research Communications

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Immunotherapy may be promising for the treatment of some GBM patients, however, there is a need for non-invasive neuroimaging techniques to predict immunotherapeutic responses. The effectiveness of most immunotherapeutic strategies requires T-cells activation. Therefore, we aimed to evaluate an early marker of T-cell activation, CD69, for its use as an imaging biomarker of response to immunotherapy for GBM. Herein, we performed CD69 immunostaining on human and mouse T-cells following in vitro activation and post immune-checkpoint inhibitors (ICI) in an orthotopic syngeneic mouse glioma model. CD69 expression on tumor-infiltrating leukocytes was assessed using single-cell RNA sequence (scRNA-seq) data from recurrent GBM patients receiving ICI. Radiolabeled CD69 antibody (Ab) positron emission tomography/computed tomography (PET/CT) imaging (CD69 immuno-PET) was performed on GBM-bearing mice longitudinally to quantify CD69 and its association with survival following immunotherapy. We show CD69 expression is upregulated upon T-cell activation and on tumor-infiltrating lymphocytes (TILs) in response to immunotherapy. Similarly, scRNA-seq data demonstrated elevated CD69 on TILs from ICI-treated recurrent GBM patients as compared with TILs from control cohorts. CD69 immuno-PET studies showed a significantly higher tracer uptake in the tumors of ICI-treated mice compared with controls. Importantly, we observed a positive correlation between survival and CD69 immuno-PET signals in immunotherapy-treated animals and established a trajectory of T-cell activation by virtue of CD69-immuno-PET measurements. Our study supports the potential use of CD69 immuno-PET as an immunotherapy response assessment imaging tool for GBM patients.

show abstract

“… 3 In addition, upcoming techniques such as FDG-PET (fluorodeoxyglucose positron emission tomography) and whole-body imaging can detect metastases in an early phase with increased accuracy. 5-7 For example, in patients with breast cancer, whole body imaging causes an increase in diagnoses of metastatic disease in asymptomatic patients. 6 , 7 …”

Section: Introductionmentioning

confidence: 99%

Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis

Augustinus,

Thurairajah,

Besselink

et al. 2023

The Oncologist

View full text Add to dashboard Cite

Background Due to increased use of imaging, advanced stages of cancer are increasingly being diagnosed in an early, asymptomatic phase. Traditionally, chemotherapy is started immediately in these patients. However, a strategy wherein chemotherapy is withheld until symptoms occur may be beneficial for patients in terms of quality of life (QOL). A systematic review regarding optimal timing of chemotherapy including survival and QOL is lacking. Methods We systematically searched PubMed, EMBASE, and Cochrane for studies investigating the timing of start of chemotherapy in asymptomatic patients with advanced cancer. Overall survival (OS) was abstracted as primary, QOL, and toxicity as secondary outcomes. A meta-analysis was performed on OS. QOL was described using the global health status derived from the EORTC-QLQ-C30 questionnaire and toxicity as grade 3-4 adverse events. Results Overall, 919 patients from 4 randomized controlled trials and 1 retrospective study were included. The included studies investigated colorectal cancer (n = 3), ovarian cancer (n = 1), and gastric cancer (n = 1). Pooled analysis demonstrated no significant differences in OS between delayed and immediate start of chemotherapy (pooled HR: 1.05, 95% CI, 0.90-1.22, P = .52). QOL, evaluated in 3 studies, suggested a better QOL in the delayed treatment group. Toxicity, evaluated in 2 studies, did not differ significantly between groups. Conclusion This meta-analysis confirms the need for prospective studies on timing of start of chemotherapy in asymptomatic patients with advanced cancer. The limited evidence available suggests that delayed start of chemotherapy, once symptoms occur, as compared to immediate start in asymptomatic patients does not worsen OS while it may preserve QOL.

show abstract

Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

Cited by 15 publications

References 38 publications

Factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: A multicenter retrospective study

Factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: A multicenter retrospective study

Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma

Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis

Contact Info

Product

Resources

About